Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH. de Vries Schultink AH, et al. Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22. Breast Cancer Res Treat. 2017. PMID: 28005246 Free PMC article.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC. Baird RD, et al. Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439579 Clinical Trial.
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.
de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. de Vries Schultink AH, et al. Eur J Clin Pharmacol. 2016 Jun;72(6):645-53. doi: 10.1007/s00228-016-2030-4. Epub 2016 Feb 26. Eur J Clin Pharmacol. 2016. PMID: 26915815 Free PMC article. Review.
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR. de Vries Schultink AHM, et al. Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5. Invest New Drugs. 2018. PMID: 29728897 Free PMC article.
18 results